Reduced anxiety level by therapeutic interventions and cell-mediated immunity in panic disorder patients

Psychotherapy and Psychosomatics

Volumn 73, Issue 5, 2004, Pages 286-292

  Koh, Kyung Bong ^a   Lee, Youngjoon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Antianxiety agent; Cell mediated immunity; Cognitive behavioral therapy; Panic disorder; Reduced anxiety

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE; ETHYL LOFLAZEPATE; INTERLEUKIN 12; PHYTOHEMAGGLUTININ;

ADULT; ANXIETY; ARTICLE; BEHAVIOR THERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RESPONSE; FEMALE; HAMILTON SCALE; HUMAN; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; MALE; MEASUREMENT; MENTAL PATIENT; PANIC; PRIORITY JOURNAL; RANDOMIZATION; TREATMENT OUTCOME;

ADULT; BENZODIAZEPINES; COGNITIVE THERAPY; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PANIC DISORDER; PHYTOHEMAGGLUTININS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 4043048801     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078845     Document Type: Article

References (38)

1. La Via MF, Workman EW, Lydiard RB: Subtype response to stress-induced immunodepression. Funct Neurol 1992;7(suppl 3):19-22.
2. Fawzy FI: Behavior and immunity; in Kaplan HI, Sadock BJ (ed): Comprehensive Textbook of Psychiatry. Baltimore, Williams & Wilkins, 1995, pp 1559-1570.
3. Linn BS, Linn MW, Jensen J: Anxiety and immune responsiveness. Psychol Rep 1981;49:969-970.
4. La Via MF, Munno I, Lydiard RB, Workman EW, Hubbard JR, Michel Y, Paulling E: The influence of stress intrusion on immunodepression in generalized anxiety disorder patients and controls. Psychosom Med 1996;58:138-142.
5. Marazziti D, Ambrogi F, Vanacore R, Mignani V, Savino M, Palego L, Cassano GB, Akiskal H: Immune cell imbalance in major depressive and panic disorders. Neuropsychobiology 1992;26:23-26.
6. Andreoli A, Keller SE, Taban C, Rabaeus M, Garrone G: Immune function in major depressive disorder: Relation to panic disorder co-morbidity. Biol Psychiatry 1990;27(suppl 9A):95A.
7. Ramesh C, Yeragani VK, Balon R: A comparative study of immune status in panic disorder patients and controls. Acta Psychiatr Scand 1991;84:396-397.
8. Rapaport MH: Circulating lymphocyte phenotypic surface markers in anxiety disorder patients and normal volunteers. Biol Psychiatry 1998;43:458-463.
9. Rapaport MH, Stein MB: Serum cytokine and soluble interleukin-2 receptors in patients with panic disorder. Anxiety 1994;1:22-25.
10. Schleifer SJ, Keller SE, Scotte BJ, Vecchione J: Lymphocyte function in panic disorder. Biol Psychiatry 1990;27(suppl 9A):66A.
11. Brambilla F, Bellodi L, Perna G, Battaglia M, Sciuto G, Diaferia G, Petraglia F, Panerai A, Sacerdote P: Psychoimmunoendocrine aspects of panic disorder. Neuropsychobiology 1992;26:12-22.
12. Fyer AJ, Mannuzza S, Coplan JD: Panic disorders and agoraphobia; in Kaplan HI, Sadock BJ (ed): Comprehensive Textbook of Psychiatry. Baltimore, Williams & Wilkins, 1995, pp 1191-1204.
13. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Press, 1994.
14. 14van Balkom AJLM, Bakker A, Spinhoven P, Blaauw BMJW, Smeenk S, Ruesink B: A meta-analysis of the treatment of panic disorder with or without agoraphobia: A comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis 1997;185:510-516.
15. Biondi M, Picardi A: Increased probability of remaining in remission from panic disorder with agoraphobia after drug treatment in patients who received concurrent cognitive-behavioral therapy: A follow-up study. Psychother Psychosom 2003;72:34-42.
16. Heldt E, Manfro GG, Kipper L, Blaya C: Treating medication-resistant panic disorder: Predictors and outcome of cognitive-behavior therapy in a Brazilian public hospital. Psychother Psychosom 2003;72:43-48.
17. Bakker A, Spinhoven P, van der Does AJW, van Balkom AJ, van Dyck R: Locus of control orientation in panic disorder and the differential effects of treatment. Psychother Psychosom 2002;71:85-89.
18. Otto MW, Hong JJ, Safren SA: Benzodiazepine discontinuation difficulties in panic disorder: Conceptual model and outcome for cognitive-behavior therapy. Curr Pharm Des 2002;8:75-80.
19. Kampman M, Keijsers GP, Hoogduin CAL, Hendriks G: A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry 2002;63:772-777.
20. Rohatiner AZS, Prior PF, Burton AC: Central nervous system toxicity of interferon. Br J Cancer 1983;47:419-422.
21. Mefford IN, Heyes MP: Increased biogenic amine release in mouse hypothalamus following immunological challenge: Antagonism by indomethacin. J Neuroimmunol 1990;27:55-61.
22. Oppenheim JJ, Ruscetti FW, Faltynek C: Cytokines; in Stites DP, Terr AI (ed): Basic and Clinical Immunology. East Norwalk, Appleton & Lange, 1991, pp 78-100.
23. Kim KI, Kim JH, Won HT: Korean Manual of Symptom Checklist-90-Revision. Seoul, Chung Ang Aptitude, 1984, pp 1-39.
24. Derogatis LR, Rickels K, Rock AF: The SCL-90 and the MMPI: A step in the validation of a new self-report scale. Br J Psychiatry 1976;128:280-289.
25. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
26. Craske MG, Barlow DH: Mastery of Your Anxiety and Panic. New York, Greywind, 1990.
27. Koh KB, Min SK, Lee HY: A double-blind comparison of antianxiety effect between ethyl loflazepate and diazepam. J Korean Neuropsychiatr Assoc 1989;28:231-236.
28. Lambert PA, Wolf R: Trial of ethyl loflazepate in psychiatric pathology in the treatment of anxiety states. Psychol Méd 1981;13:2205-2212.
29. Filoche B: A new tranquilizer: Ethyl loflazepate in gastroenterology, double-blind trial against bromazepam. Psychol Méd 1983;15:797.
30. Remy H: Victan in general practice: Results of a study involving 4,016 anxious patients. Gaz Méd 1984;91:16-22.
31. Williams RM, Kraus LJ, Inbar M: Circadian bioperiodicity of natural killer cell activity in human blood (individually assessed). Chronobiologia 1979;6:17.
32. Koh KB, Lee BK: Reduced lymphocyte proliferation and interleukin-2 production in anxiety disorders. Psychosom Med 1998;60:479-483.
33. Surman OS, Williams J, Sheehan DV, Storm TB, Jones KJ, Coleman J: Immunological response to stress in agoraphobia and panic attacks. Biol Psychiatry 1986;21:768-774.
34. Schleifer SJ, Keller SE, Scott BJ, Cottrol CH, Vallente TJ: Familial Traumatic Injury and Immunity. New Research (Abstract). San Francisco, American Psychiatric Press, 1989.
35. Koh KB: The relationship between stress and natural killer-cell activity in medical college students. Korean J Psychosom Med 1995;3:3-10.
36. Koh KB: The relationship of stress-induced hypothalamic-pituitary-adrenal axis function with cell-mediated immunity. J Korean Neuropsychiatr Assoc 2001;40:857-866.
37. Koh KB, Lew SH: The effect of vitamin B-complex on stress-induced immune alteration. Korean J Psychosom Med 1999;7:196-202.
38. Koh KB: Emotion and immunity. J Psychosom Res 1998;45:107-115.